文献速递胸部肿瘤放疗姑息放疗与转移瘤

既往肺部照射范围与有癌症史的COVID-19患者死亡率的关系

Extent of Prior Lung Irradiation and Mortality in COVID-19 Patients With a Cancer History.
PubMed 文献 · Adv Radiat Oncol · 2020-05-20

本研究纳入2020年3月14日至4月15日期间在本机构COVID-19检测阳性且既往在本科室接受过癌症放疗的107例患者,中位随访7天,观察到24例死亡,COVID-19检测后14天生存率为66%。平均肺剂量每增加1 Gy死亡风险增加(HR=1.1,P=.002),肺癌诊断(HR=3.0,P=.034)和检测前1个月至1年内接受放疗(HR=3.4,P=.013)与死亡风险增加相关,死亡风险与平均肺放疗剂量呈近线性关系。

要点

  • 有癌症放疗史的COVID-19患者预后差,14天生存率为66%。
  • 平均肺剂量每增加1 Gy,死亡风险HR=1.1(P=.002)。
  • 肺癌诊断及检测前1个月至1年内放疗与死亡风险增加相关。

核心结论

  • 有癌症放疗史的COVID-19患者预后差,死亡风险似乎与肺部照射范围相关。

研究设计与样本

  • 回顾性分析2020年3月14日至4月15日在本机构COVID-19检测阳性且既往在本科室接受癌症放疗的107例患者。
  • 采用Cox回归模型识别COVID-19诊断后死亡的预测因素,采用logistic模型描述平均肺放疗剂量与14天死亡风险的关联。

主要发现

  • 中位随访7天(存活患者自COVID-19诊断起),观察到24例死亡,COVID-19检测后14天生存率为66%。
  • 平均肺剂量增加与死亡风险增加相关(HR每Gy=1.1,P=.002)。
  • 肺癌诊断与死亡风险增加相关(HR=3.0,P=.034)。
  • COVID-19检测前1个月至1年内接受放疗与死亡风险增加相关(HR=3.4,P=.013)。
  • 生存模型显示COVID-19诊断后死亡风险与平均肺放疗剂量呈近线性关系。

临床怎么用

  • 对既往接受肺部放疗的COVID-19癌症患者应认识其死亡风险较高。
  • 平均肺放疗剂量、肺癌诊断及近期放疗史可用于风险分层参考。

局限性

  • 单中心回顾性分析,样本量107例,中位随访仅7天。
  • 作者指出需验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There have been nearly 200,000 deaths worldwide so far from coronavirus disease 2019 (COVID-19), which is caused by a coronavirus called SARS-CoV-2. Cancer history appears to be a poor prognostic factor for COVID-19 patients, although the reasons for this are unclear. In this report, we assess whether extent of prior lung irradiation is a risk factor for death as a result of COVID-19 infection. METHODS AND MATERIALS: Patients who tested positive for COVID-19 between March 14 and April 15, 2020, at our institution and who previously received radiation therapy for cancer in our department were included in this analysis. Patient characteristics and metrics describing the extent of lung irradiation were tabulated. Cox regression models were used to identify predictors of death after COVID-19 diagnosis. A logistic model was used to characterize the association between mean lung radiation therapy dose and 14-day mortality risk after COVID-19 diagnosis. RESULTS: For the study, 107 patients met the inclusion criteria. With a median follow-up of 7 days from COVID-19 diagnosis for surviving patients, 24 deaths have been observed. The actuarial survival rate 14 days after COVID-19 testing is 66%. Increasing mean lung dose (hazard ratio [HR] per Gy = 1.1, P = .002), lung cancer diagnosis (HR = 3.0, P = .034), and receiving radiation therapy between 1 month and 1 year before COVID-19 testing (HR = 3.4, P = .013) were associated with increased risk of death. Our survival model demonstrates a near linear relationship between mortality risk after COVID-19 diagnosis and mean lung radiation therapy dose. CONCLUSIONS: COVID-19 patients with a history of radiation therapy for cancer have a poor prognosis, and mortality risk appears to be associated with extent of lung irradiation. Validation of these findings will be critical as the COVID-19 pandemic continues.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kabarriti R, Brodin NP, Maron MI, et al. Extent of Prior Lung Irradiation and Mortality in COVID-19 Patients With a Cancer History. Adv Radiat Oncol. 2020. PMID: 32775778. doi:10.1016/j.adro.2020.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。